Why You Can't Sleep on Peptides

Your body runs on glucose the way a car runs on fuel, and at night, when you haven't eaten in hours, it's running entirely off what's stored and what it can manufacture on demand. Most nights that system works quietly and you never notice it. But introduce the right peptide at the wrong time, and that system starts misfiring at 2am, which is exactly when people are waking up and blaming their sleep.

The actual mechanism is a rescue response, not a sleep disorder.

When blood glucose drops below a threshold your body considers safe, your adrenal glands release cortisol and adrenaline to drive it back up. Cortisol signals the liver to push glucose into the bloodstream, adrenaline amplifies the response, and together they pull you out of whatever sleep stage you were in. That's not insomnia. That's your body treating low blood sugar like an emergency, because to your survival systems, it is.

So the question becomes: why would peptides cause your blood sugar to crash in the first place? The answer depends entirely on which class of compound you're taking, because two different mechanisms are at work and they are not the same problem.

The first mechanism involves something called incretin mimetics, which are compounds like semaglutide, tirzepatide, and retatrutide that mimic gut hormones to suppress appetite and lower blood sugar. They work remarkably well at that job. The phase 2 retatrutide trial published in the New England Journal of Medicine showed a mean weight loss of 24.2 percent at the highest dose, and the appetite suppression across all dose groups was significant. That appetite suppression is the intended effect, but it creates a downstream problem most people don't anticipate: they simply stop eating enough without realizing it.

When caloric intake drops substantially, there's less substrate coming in and less glycogen getting stored in the liver and muscle going into the overnight fast. So the buffer that normally keeps blood sugar stable through eight hours of sleep is shallower than usual, and blood sugar bottoms out earlier in the night.

Now if you're thinking "I'm low carb, so this doesn't apply to me," that logic is half right and half wrong. Your body has a backup system called gluconeogenesis, which is the liver manufacturing new glucose from amino acids, glycerol, and lactate when dietary carbohydrate isn't available. People who are adapted to low carb or ketogenic eating have robust gluconeogenic capacity, and their blood sugar tends to stay stable overnight without relying on glycogen stores. The variable isn't the macronutrient ratio. The variable is total caloric intake. When a drug crushes appetite so effectively that someone is eating barely anything at all, gluconeogenesis can't fully compensate, especially later in the night when substrates run low.

The second mechanism is different in origin but nearly identical in effect, and it involves growth hormone secretagogues like CJC-1295, ipamorelin, and tesamorelin.

These compounds work by stimulating your pituitary gland to produce a pulse of growth hormone, and most people inject them before bed to align that pulse with the natural GH surge that occurs during deep sleep. That timing logic makes physiological sense. The problem is that growth hormone is anti-insulin by nature.

The mechanism was documented clearly in a 1990 Diabetologia study by Perriello and colleagues. When they suppressed nocturnal GH spikes with somatostatin in Type 1 diabetics, the dawn phenomenon disappeared. When they restored the GH spikes, it came back. Hepatic glucose production increased approximately 30 percent in response to the GH. What growth hormone does, mechanistically, is reduce the liver's and peripheral tissues' sensitivity to insulin, which means glucose that would normally be cleared and stored stays circulating, and the regulatory feedback loops that normally keep blood sugar stable start oscillating instead of dampening.

Moller and Jorgensen's 2009 review in Endocrine Reviews explains the biochemical pathway behind this: GH drives increased free fatty acid flux from adipose tissue, and elevated free fatty acids compete with glucose at the cellular level in a way that impairs insulin-mediated glucose uptake. The result is transient insulin resistance that peaks several hours after the GH pulse fires, which, if you inject at bedtime, lands squarely in the middle of the night.

So instead of steady blood sugar through the night, you get a swing, and the descent from that swing triggers the same cortisol and adrenaline rescue response as any other hypoglycemic event.

When someone is on both an incretin and a GH secretagogue at the same time, both mechanisms are operating simultaneously. Reduced glycogen stores from undereating combine with GH-induced insulin resistance and the resulting oscillation, and the probability of a nocturnal blood sugar event climbs considerably.

The practical fix starts with which mechanism is causing the problem.

If you're on an incretin and waking up in the middle of the night, the first thing to audit is whether you're actually eating enough across the day. Not just your macros, but total caloric volume. The appetite suppression these drugs produce is so effective that significant undereating can happen without any subjective feeling of restriction. Tracking food intake for a few days is worth doing to see where you actually are.

If you're on a GH secretagogue, moving the injection window from right before bed to two or three hours earlier can reduce the overlap between the GH-induced insulin resistance peak and your deepest overnight sleep. The GH pulse still fires, the metabolic benefit is preserved, but the timing of the blood sugar oscillation shifts away from the hours where cortisol will pull you awake. A small snack containing protein and fat before bed can also provide substrate to buffer both scenarios, giving gluconeogenesis more raw material to work with and blunting the rate of glucose decline.

Most people who start peptides get told the sleep disruption is a known side effect or that their body will adjust. Sometimes it does, but not because of adaptation to the compound. It adjusts when eating patterns normalize or when timing gets dialed in. The sleep was never the problem. The blood sugar was.

And once you understand that, the solution stops being "take a sleep supplement" and becomes "fix the fuel system." Those are very different interventions with very different outcomes.

---

References

1. Perriello G, De Feo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 diabetes mellitus by decreasing hepatic and extrahepatic sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990;331:52-59. Finding: Suppressing nocturnal GH spikes with somatostatin abolished the dawn phenomenon; restoring GH spikes reproduced it. Hepatic glucose production increased approximately 30%. Source
2. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;302:152-177. Finding: GH antagonizes insulin's hepatic and peripheral effects via increased free fatty acid flux and uptake. Source
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;3896:514-526. Finding: 24.2% mean weight loss at 12mg dose; significant appetite suppression documented across all dose groups. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness